Aerie Pharmaceuticals reported $1.64M in Interest Expense on Debt for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Aerie Pharmaceuticals AERI:US $ 1.64M 0M
Alimera Sciences ALIM:US $ 1.38M 0.02M
Insmed INSM:US $ 3.36M 66K
Novartis NOVN:VX 202M 1000K
Pacira Pharmaceuticals PCRX:US $ 8.83M 1.41M
Regeneron Pharmaceuticals REGN:US $ 13.1M 0.5M
Revance Therapeutics RVNC:US $ 3.87M 1.94M
Supernus Pharmaceuticals SUPN:US $ 1.81M 0.66M
Teva Pharmaceutical Industries TEVA:US $ 225M 13M
Valeant Pharmaceuticals VRX:CN $ 527.75M 165.75M
Zoetis ZTS:US $ 53M 0M